|
|
|
Abstract Objective To investigate the effect of trimetazidine in improving the life quality of patients with coronary disease after coronary stent implantation. Methods Seventytwo patients implanted with coronary stent were randomly divided into two groups: treatment group and control group. Patients in the treatment group took trimetazidine combined with essential drugs of coronary heart disease persistently while the ones in the control group only accepted therapy with essential drugs. Before the operation one year later, questionnaire survey was performed with the MOS item short from health survey(SF-36). Results In terms of each basic value in SF-36 health survey table, there was no statistically significant difference between the two groups before the implantation(P＞0.05). One year after the operation, there were statistically significant differences in the indices of physiological functions, physical pain, overall health, vitality and social ability in SF-36 health survey table(P＜0.05). Conclusion Taking trimetazidine can improve the life quality of patients with coronary heart disease after coronary stent implantation.
|
|
|
|
|
|
| [1] 赵振彪,张咏梅,赵大卫,等.冠心病患者冠状动脉支架术后12个月生活质量评价[J].中国老年学杂志,2005,25(8):971-972.[2] Favarato ME, Hueb W, Boden WE, et al．Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategiesMASS Ⅱ trial[J].Int J Cardiol,2007,116(3):364-370．[3] 庞红,林华,张金枝,等.曲美他嗪对稳定型劳力性心绞痛患者心肌缺血的影响[J].临床心血管病杂志,2001,17(2):68-69.[4] 李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试[J].中华预防医学杂志,2002,36(2):109-113.[5] Ren XS, Amick B 3rd,Zhou L,et al．Translation and psychometric evaluation of a Chinese version of the SF36 Health Survey in the United States[J].J Clin Epiderniol，1998，51(11)：1129-l138．[6] 陆益花,严健华,孙瓅贤,等.冠心病患者中文版SF-36和QOL-35量表的相关分析[J].中华流行病学杂志,2010,31(11):1292-1295[7] Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives[J]. Angiology,2015,66(3):204-210.[JP][8] McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an antianginal agent [J]. Eur Heart J Cardiovasc Pharmacother,2016,2(4):266-272.[9] Hao J, Du H, Li WW, et al. Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention[J]. Eur Rev Med Pharmacol Sci, 2015 ,19(23):4642-4646.[10] Demirelli S, Karakelleo[KG-*4]g[DD(-*2][DD)]lu S, Gündo[KG-*4]g[DD(-*2][DD)]du F,et al. The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with nonST segment elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Korean Circ J, 2013,43(7):462-467.[11] Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention[J]. Am J Cardiovasc Drugs, 2007,7(2):143-150.[12] Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3ketoacyl coenzyme A thiolase [J]. Circ Res, 2000 ,86(5):580-588. |
|
|
2016, Vol. 25 
